INTRODUCTION
The field of solid organ transplantation is based largely on the concept that replacement of irreversibly damaged organ in an otherwise 'healthy" recipient can significantly prolong survival or even cure some diseases. Although the hope for clinical success is based on this premise. many allograft recipients suffer from recurrence of the original disease. For example. chronic viral hepatitis types Band C almost invariably attack the new liver after hepatic replacement [I. 2] . This unfortunate reality illustrates the importance of a systemic. or nonlocal. perspective in transplantation biology: a specific disease may primarily manifest in a single organ. but for many disorders this simply represents a local manifestation of a more pervasive problem. An exception to this generalization is organ-specific toxic injury or organ-based metabolic diseases where replacement of the defective organ corrects a systemic problem and brings about a true cure.
A systemic perspective is also of importance in the study of transplantation physiology. including allograft immunobiology. For example. insulin secreted by islet allografts can regulate the recipient blood sugar: and a new liver will receive blood and nutrients from the recipient intestines. from which it will synthesize cholesterol used to construct new 'recipient' cells. Fortunately. clinical physicians rarely have to be concerned about physiological compatibility between the donor and recipient. Most of the complex systems involved have 'nonlocal' properties that enable a donor organ to spontaneously adjust to its new environment. The integration occurs so naturally that one rarely even thinks about the interface between donor and recipient. unless something goes wrong.
The most important exception to the above generalization is the immune system: its 'local' properties result in an inability to spontaneously integrate the donor with the recipient. and vice versa. which in turn leads to significant problems for the transplant surgeon. Unless the patient is heavily immunosuppressed, the allograft is eventually rejected. There are. however. situations in experimental animals where allografts are accepted without immunosuppression. and in humans where immunosuppression can be completely withdrawn and the allografts function for the lifetime of the recipient. Thus . the local properties of the immune system were not designed to frustrate transplant clinicians. instead. they can be predictably redesigned under certain circumstances.
Consequently. the entire field of clinical transplantation could be thought of as an experiment conducted to investigate the local properties of the immune system. among others. including the role of MHC antigens and the consequences of MHC antigen expression on different cell types. Since these antigens. as well as sex chromosomes. can be used to mark the genetic fidelity of an individual cell. double labeling techniques can be used to trace specific donor and recipient cell types after solid organ transplantation to assess problems with integration. Discoveries made using this technology have brought together two previously unlinked research fields in transplantation immunology: the deleterious and the beneficial functions of donor hematolymphoid cells. The sections below overview both lines of investigation and highlight the role of dendritic cells (DC) in allograft rejection and acceptance.
ORGAN-BASED IMMUNE NETWORKS
Before proceeding directly to a discussion of the role of DC in transplantation. it is important first to briefly overview organ-based immune physiology. This refers to a dynamic network of hematolymphoid cells that travel into and out of. and transiently occupy. the interstitium of all solid organs. These cells monitor the microenvironment and communicate with central lymphoid organs. and regional lymph nodes via the circulatory system and lymphatics [3] . An understanding of this system is of particular importance in organ transplantation. since problems with assimilation of the donor immune system affect many aspects of transplantation biology. as well as patient management. Examples include the susceptibility to rejection. the clinical and histopathological manifestations of both acute and chronic rejection. infections. and the interface between infection and rejection.
Organ-based immune cells are primarily derived from progenitors that migrate from the bone marrow. although maturation from local precursors. including intraorgan hematopoietic stem cells. can also contribute to this pool. Even in an adult. the liver has enough hematopoietic stem cells to fully reconstitute. for the long term. a lethally irradiated recipient [4.5] . The important point is that intraorgan immune cells are a dynamic population: they continuously mature and migrate and therefore must ultimately be maintained by a stem cell population.
Normal physiology accounts for the considerable variation among different organs in the quantity and quality of organ-based immune cells [6.7] . Organs in direct contact with the external environment. such as the lungs and intestines. have an exaggerated complement of organ-associated lymphoid tissue. generally termed 'mucosal-associated lymphoid tissue'. After contact with commensal bacteria in neonatal life. the immune cells spontaneously arrange into an organized complex structure. which is identical to that seen in lymph nodes. replete with B cell follicles and T cell-rich interfollicular zones rich in DC [8-10]. Thereafter. a delicate balance is maintained between reaction to antigens from the environment and local tissue damage. The liver. on the other hand. is indirectly exposed to the external environment. since it drains blood from the intestines. It is richly endowed with a large component of cells from the monocyteimacrophage lineage. consistent with its role as a filter of various opsonized materials. including microorganisms. activated platelet aggregates. and coagulated proteins [II] . Heart [6. 7.12.13 ] and kidneys [6.14.15 ) also have considerable. but less well developed immune networks in comparison to the above organs.
Common to vascularized organs is a population of DC precursors at various stages of maturation located in the interstitial connective tissue [14] [15] [16] [17] [18] [19] . The 'immature' state of many intraorgan DC [18.20-22] . except for those in the lymphoid tissue of the lung and intestines [18.19J . is characterized by phagocytic capacity. which is absent in mature DC [U-'. 21. 22) : relatively inefficient stimulatory capacity in a mixed leukocyte reaction (MLR) [22J: and low density of MHC class II (21) or costimulatory molecule expression [19J. Organ-based DC precursors can also he identified with a series of monoclonal antibodies directcd at certain differentiation markers. covered elsewhere in this book.
Dendritic cells and their precursors reside near terminal lymphatics throughout the interstitium of organs. and are concentrated near draining efferent lymphatic vessels in the adventitia of arteries: epithelial-lined conduits that are in contact with the external environment, such as the mucosal-associated lymphoid tissue of the lungs [23] and intestines [18. 19] : and portal tracts of the liver [17. 21. 24) . At these sites. they monitor the microenvironment for foreign. or dangerous antigens [25] . exposure to which stimulates DC maturation and migration via efferent lymphatics to the paracortex of regional lymph nodes where they stimulate a T cell response [18.22.26-30] . The factors involved in DC activation. maturation, and migration are covered in more detail in Chapter II. Thus. the vasculature and lymphatics represent important lines of communication between the intraorgan immune network. the regional lymph nodes. and eventually the thymus and spleen.
HEMATOLYMPHOID ANO DENDRITIC CELLS AS POTENTIATORS AND FACILITATORS OF REJECTION

Acute 'Cellular' Rejection
When an organ becomes an allograft. the nascent hematolymphoid cells become known as 'passenger leukocytes'. The idea that these particular donor cells are especially immunogenic was first proposed by Snell [31] . Steinmuller (32) provided experimental evidence for this concept by showing that chimeric donor skin allografts in which the passenger leukocytes were allogeneic. but the epidermal cells were syngeneic to the recipient. resulted in permanent graft acceptance. However. the recipients became sensitized to the alloantigens on the hematopoietic cells.
The relative importance of passenger leukocytes in precipitating rejection was further addressed by Guttmann et al. [33] , who constructed chimeric donor organs by lethally irradiating rats and reconstituting them with allogeneic bone marrow. He showed that the 'immunogenicity' of the organs could be greatly reduced when the passenger leukocytes were syngeneic to the recipient. Several other experimental manipulations also showed conclusively that the passenger leukocytes were more immunogenic than the parenchyma. These included pretransplant ill l'itro culturing to eliminate or reduce the complement of passenger leukocytes [34] [35] [36] provided a key piece of evidence bringing DC to the forefront as the passenger leukocyte prototype. They showed that the immunogenicity of long-surviving enhanced (AS X AUG)F I renal allografts retransplanted into secondary AS recipients could he restored hy the injection of as few as I x 10 4 to 5 X 10 4 DC of donor strain derived from afferent lymph [40] . In contrast. neither the passenger volume of donor strain blood. nor 5 x 10° T-or B-lymphocytes were able to do so. thereby demonstrating more than a 100-fold difference in immunogenic potency. These findings were consistent with observations about the functional activities of DC originally made by Steinman and colleagues [41] [42] [43] and later confirmed by many others.
Disrupted Local Lymphatics
It should be remembered that donor organ harvesting and reimplantation disrupts the dferent lymphatic channels. This blocks an important migratory circuit for immune cells that are either already present in or enter the allograft interstitium. until connections with regional lymph nodes are reestablished within 2-3 weeks [44-48]. In fact. efferent lymphatic disruption. along with ischemic injury contributes to a 'reimplantation' response. which by itself can precipitate activation of the intraorgan immune network [46-51]. Thus. this purely mechanical problem can. in some respects. simulate an antigen-driven immune response [51] and is one of the first difficulties. but by no means the only one. encountered when the immune system of the donor attempts assimilation with that of the recipient.
The presence of MHC. adhesion and costimulating molecules on DC causes them to spontaneously form clusters with and directly activate allogeneic lymphocytes [24.52] . In an allograft. activated recipient T cells in such clusters proliferate [24] and produce cytokines that recruit other immune cells that have the potential to damage the organ. In fact. the distribution of mononuclear cells at the initiation of acute rejection reflects the intraorgan distribution of DC [24.52] : in kidney allografts it preferentially localizes to the cortex and outer medulla [14. 15] . whereas. in the liver. portal tracts and perivenular regions are preferentially targeted [17.24,53] . Conversely. the absence of renal cortex or portal tracts in an allograft kidney or liver biopsy. respectively. renders such samples inadequate for the evaluation of rejection. Altogether. this process is referred to as 'peripheral sensitization'. or recognition of the allograft in the periphery via direct alloantigenic stimulation. Subsequently, upregu!ation of adhesion molecules on the surrounding vasculature and recruitment of lymphoid and nonlymphoid effector cells and local tissue damage signal the development of acute 'cellular' rejection.
In organs with mucosal-associated lymphoid tissue, such as the lung and intestines, recipient lymphocytes trafficking into the allograft following the same migratory routes as they normally would: they enter the T cell-dependent areas of the bronchial (BALT) and mucosal (MALT) associated lymphoid tissue. respectively [12.54-58]. Here they encounter donor DC and participate in a bidirectional . ill l'il'O mixed leukocyte response' [12.54-59] . which is the same type of response as described ahove for the interstitium of organs except that the surrounding microenvironment contains immunologically active donor T-and B-lymphocytes.
Passenger Leukocytes
Passenger leukocytes from the donor immune network. including DC. leave the allograft. either hematogenously or via intact regional efferent lymphatics that drain to c/ol/or regional lymph nodes transplanted ('1/ h/ol' with the allograft [56. 57.59 ]. Larsen and colleagues [60.61] were the first to show that donor DC frol11 a heart allograft migrate hematogenously to the recipient spleen. The same thing occurs after transplantation of a liver allo-or xenograft [24.62] . Donor DC leaving these allografts migrate to the periarterial lymphatic sheath and marginal zone of the spleen. where their appearance is associated with a proliferative response in the recipient lymphoid cells ( 20.2) . This is evidenced hy their ability to reconstitute lethally irradiated experimental animal recipients [4.5] and to convert the blood type of human recipients [64] . Thus. at the progenitor level. donor cells will have access to the recipient bone marrow. to regional and distant lymph nodes. and even to the thymic medulla [3. 63.65-68] .
Once recipient T cells are activated within the allograft and rejection effector mechanisms begin to damage the organ, there is an increased production of lymph and disruption of the lymphatic and capillary microvascular endothelial junctions. This retards immune cell traffic and lymph fiow [45-4l:i. 69 -71] and contributes to the reappearance of graft edema and swelling typically seen during acute rejection [45. [69] [70] [71] [72] . The result is an endless cycle of immune activation and damage. graft edema. retarded immune cell trafficking and diminished blood flow. Unless interrupted by increased immunosuppression. the process usually leads to allograft failure.
Considering the completeness of the data outlined above. it was reasonable to conclude that the passenger leukocyte popUlation should he removed from the allograft before transplantation. Thus. various types of irradiation [73] and monoclonal antibodies directed at common leukocyte (74-76] or MHC class II [77-79] antigens were used in an effort to deplete these cells. In general. all of these pretreatment regimens prolonged allograft survival. but the long-term beneficial effects were less than expected.
Targeting Donor DC
Blocking costimulatory molecules such as the B7 family [80] [81] [82] [83] [84] [85] and CD40 [81. 86] 
f ;j~ ':.:;,::,!=~::--.~':-' ~~-I actual allograft \'asculopathy [82] [83] [84] [85] suggests that tolerance without a susceptibility to CR has not been achieved. Nevertheless. this line of research represents an important advance in our understanding. of how acute rejection damages an allograft.
It is interesting to note that the beneficial effect of costimulatory molecule blockade was dimillished by immunosuppression and was augmenTed by the addition of donor antigen in the form of donor splenocytes [85] . In addition. the B7-CD28 blockade does not completely stop cytokine mRNA production within the allog. raft . Although this line of reasoning has several important conceptual flaws. it is based on the concept that more than one signal is needed to trigger T cell activation and proliferation [25] .
III I'ilm. presentation of antigen without proper costimulation can result in anergy [25] . 
Transitional Phase
Since passenger leukocytes are bone marrow-derived or stem cell-dependent. they exist for a relatively short period in the periphery. Thus. replacement of the donor intraorgan immune network (including DC) after transplantation with similar recipient cells is an f'~~~ .,;:;~::~; ':,. ' .~ , expected finding [57. [110] [111] [112] [113] [114] [115] [116] [117] [118] . Indeed. this occurs to some extent in all allografts. since trafficking of immune cells is part of the normal 'nonlocal' immune physiology. However. as discussed above. when recipient T cells encounter donor DC (and vice versa). the transitional process has to be chaperoned by immunosuppressive drugs because it usually precipitates acute rejection. For DC. the replacement phenomenon likely occurs at a precursor cell stage. since mature recipient DC do not appear to home to allograft tissues [119] .
It is likely that the same factors that control activation. maturation. and migration of DC precursors in nonallograft organs contribute to donor and recipient DC trafficking in allografts. For example. it is known that the intraorgan cytokine milieu contributes to activation. recruitment. and migration of both macrophages and DC. In allografts. the cytokine-rich milieu of rejection [120] 
Chronic Rejection
Chronic rejection (CR). in any organ, can be broadly defined as a largely indolent but progressive form of allograft injury. characterized primarily by persistent but patchy inflammation of the allograft. interstitial fibrosis. fibrointimal hyperplasia of arteries. and destruction and atrophy of parenchymal elements and organ-associated lymphoid tissue [89. 120, 125] . The term chronic implies a temporally prolonged course and. in general. CR more indolently compromises organ function than acute rejection. However. it clearly develops in many cases from inadeq uately controlled acute rejection and in patients not compliant with immunosuppressive therapy. In others, CR more indolently compromises allograft function over a period of months to years. without an apparent precipitating event [89]. Our emphasis here will be on DC. The reader interested in a broader perspective of CR is referred to several recent reviews [89, [126] [127] [128] .
The intragraft inflammatory infiltrates associated with CR are often arranged into nodular aggregates, some of which contain germinal centers [89] reminiscent of the development of mucosal-associated lymphoid tissue. discussed above. Immunophenotypic analysis reveals a predominance of CD4+ and CD8~ T cells and macrophages with fewer B cells. although those present can form small primary and secondary follicles. This is in contrast to the infiltrates associated with acute rejection. which have fewer B cells and no follicles and tend to be more diffusdy distributed throughout the interstitium. lacking an organized structure.
Few studies have specifically investigated DC in chronically rejecting organs. Oguma ('I al. (129) suggested that DC of r('cipi('1It origin participated in the CR process by coordinating antigenic presentation in arteries affected by obliterative arteriopathy and in the interstitium. Subsequent studies have verified these findings and found that the number or recipient DC in chronically rejecting organs correlates directly with the overall severity of inflammation [116. 120. 130] . Moreover. the r('cipi(,1I1 DC are concentrated amidst the lymphoid aggregates [116. 120.122.129] . suggesting that they arc coordinating antigen presentation. an assumption based on the spatial relationship between the DC and the lymphoid infiltrates. These morphological and immunohistochemical observations are consistent with the concept that indirect (rather than direct). MHC-restricted alloantigen presentation importantly contributes to CR [I06-IOX]. and that chronic antigenic stimulation occurring outside the lymph nodes can result in the development of intraorgan lymphoid tissue [131. 132] . similarly to autoimmune disorders such as Hashimoto's thyroiditis. primary biliary cirrhosis. and Crohn's disease [131] .
As alluded to abovc. chronically rejecting allografts also devdop another significant problem: thc persistent or severe injury during the transitional phase selectively damages mucosal-associated lymphoid tissue normally present in the lung [12. 133] 
HEMATOLYMPHOID ANO OENDRITIC CELLS AS FACILITATORS OF TOLERANCE INDUCTION
There are two lines of transplantation research in which studies show how donor hematopoietic cells in general. and DC specifically. might induce tolerance to solid organ allografts. The first of these is activation-induced clonal deletion and the second is induction of hematopoietic chimerism.
Donor Dendritic Cells as Mediators of Peripheral Clonal Deletion
Implantation of any solid organ allograft results in a characteristic cycle of heightened immune activation. followed by evolution toward a more stable relationship between the allograft and the recipient when immunosuppression can be considerably lowered or even withdrawn [140.141] . With the understanding brought about by the appreciation of donor hematopoietic cell migration after transplantation [24. 63. 113. 142] . this prototypic series of events can likely be attributed. in large part. to the initial engagement of donor and recipient immune cells in the allograft and recipient lymphoid tissues. , t.-. -,-' __ :", -_; During this time. it is possible that the intense immune activation results in a form of clonal deletion called clonal stripping [143] . deletion or purging through apoptosis [144] [145] [146] . It might be crudely thought of as the peripheral equivalent of negative selection in the thymus. which is a very efficient means of controlling reactivity in a lymphocyte population. Current research suggests that DC may he involved in this process: blocking of costimulation on mature DC allows exhibition of their apoptosis-inducing potential and they thus may be particularly adept at mediating such a process [27. 147.148] . In fact. it is tempting to speculate that the combination of clonal deletion via apoptosis after a strong rejection reaction. followed by replacement of the intra-graft immune network (graft adaptation). ultimately causes the immune system to ignore the allograft. Unfortunately. on a practical level. the harsh reality is that. even in combination. the above mechanisms are unable to prevent rejection in the majority of long-term survivors without the aid of exogenous immunosuppression [89]. At best. there exists an uneasy truce between an adapted allograft and a recipient that can be triggered into a rejection reaction at the slightest provocation. I n the worst case. most long-term recipients are slowly rejecting their organs. This also holds true for liver allograft recipients. who are resistant to CR compared to recipients of other vascularized allografts [89. 149]: even this 'favorable' recipient population requires chronic immunosuppression in over 80% of long-term survivors [141] . Thus. while clonal deletion or stripping. veto or regulatory cells. or other mechanisms may contribute to graft acceptance in immunosuppressed recipients. they are insufficient in the majority of patients to allow cessation of immunosuppressive therapy.
Dendritic Cells as Mediators of the Effects of Hematopoietic Chimerism
Owen [150] was the first to show that twin cattle sharing a placental circulation develop chimeric immune systems. each composed of immune cells from both individuals [150] . He found that this condition enabled them to exchange other tissues without the fear of rejection. or a need for immunosuppression. When attempts were made to create chimeric immune systems in adult animals. it was quickly realized that lethal or sublethal irradiation and other harsh conditioning regimens were required to ablate the recipient immune system and to make 'physiological space' for the engraftment of infused donor bone marrow [151] [152] [153] [154] [155] [156] [157] [158] [159] . Unfortunately. this limits clinical implementation of the concept. Two major problems exist: graft-versus-host disease [ 160. 161) and the morbidity associated with the conditioning regimens [158. 162] . Current approaches to decreasing morbidity without compromising donor stem cell engraftment include lower doses of irradiation. facilitator cells [163. 164] . and/or higher doses or repeated infusions of donor bone marrow [159. 162. 165] .
Nevertheless. when donor stem cell engraftment results in long-term mixed hematopoietic chimerism. there is complete assimilation of the donor immune system in some cases. and an undeniable association with tolerance. In the mixed chimeric animals. intraorgan immune networks are composed of cells from both individuals [154, 166] . and tolerance is strictly dependent on the persistence of hematopoietic chimerism: loss of chimerism and loss of tolerance go together [167. 168] . This has been observed in humans given fetal liver cell allografts [169] [170] [171] . and in a number of small experimental animal models [151-155.157-159] .
The experimental models ha\'e been useful in determining the role of DC in tolerance induction. For example. mixed chimeric animals specifically lack donor responsiveness in a MLR. accept allografts without immunosuppression. and arc resistant to CR [I n. 173]. Central deletional tolerance is primarily responsible for these observations [154. 155. 158] . although peripheral mechanisms also likely contribute to the process [174. 175] , Thus. the situation is similar to the nontransplantation setting. where both central and peripheral mechanisms contribute to 'self' tolerance. which is a 'local' property of the immune system.
In the nontransplantation setting. central or thymic tolerance invol\'es a complex set of thymic epithelial and stromal interactions with immature T cells that first mediate positive selection of developing thymocytes. based on 'self' reactivity [176] [177] [178] [179] 
FINDINGS THAT BRIDGE THE GAP BETWEEN IMMUNOGENIC AND TOLEROGENIC DC
In the late 1980s. a series of experiments were carried out to examine the sequence of histopathological changes associated with acute intestinal allograft rejection [56. 57]. During these studies. it was necessary to distinguish between donor and recipient lymphoid cells. so that one could unravel the underlying immune pathophysiology. This was achieved with the development of a monoclonal antibody that reacted with the class II major histocompatibility antigens of most rat strains. except the Brown Norway (BN) [188] . Subsequently. it was possible to show that Lewis cells emigrated into the BN GALT and mesenteric lymph node of intestinal allografts. where they replaced cells of donor origin in the organ-based immune network. This occurred within the first several weeks after transplantation [57] . Similar findings were observed in human small-intestinal allograft recipients [112] .
The above studies prompted an investigation of the fate of donor cells that had emigrated from the allograft. Up to that time. very few such studies had appeared in the literature [24. 60. 65. 189. 190] . and all came to the same conclusion discussed above-donor passenger leukocytes. especially DC. were essentially deleterious to allograft survival because they served only to precipitate and/or amplify a rejection reaction. However. all of these studies were conducted in nonimmunosuppressed recipients, which resulted in rapid rejection of the allografts. as expected. Had similar studies been carried out on the fate of passenger leukocytes in either transiently or continuously immunosuppressed recipients. the conclusion about the role of DC in organ transplantation might have been different. In essence. that is what was done in the early 1990s.
A quick survey of available long-term experimental animal and several humans organ allograft recipients revealed a surprising finding-the donor hematolymphoid 3) . some of whom were chronically free of immunosuppressive therapy [65. 113. 166] . Moreover. the donor cells were ubiquitously distributed throughout the lymphoid and nonlymphoid tissues. and some had the characteristics of DC [65. 166] . This included a strong surface expression of MHC class II antigens. a dendritic shape. and a location in the interstitium of organs. the paracortex of lymph nodes. the thymic medulla [63. 65-68] . and the periarterial lymphatic sheath of the spleen. These are all sites where DC normally reside. Further studies by Lu and Thomson [21. 66. 191. 192] showed conclusively that DC and their precursors were included among the passenger leukocytes persisting in organ allograft recipients.
These observations led to the suggestion that 'microchimerism' or the persistence of donor hematopoietic cells was necessary. but alone not sufficient. for the induction of tolerance [I 13-115.193] . Since the donor cells persisted for decades in some patients. it was assumed that they are sustained by 'engrafted' donor stem cells transplanted with the organ (Plate 20.2) . The important conceptual point is that donor hematolymphoid cells appear to have integrated successfully into the recipient immune system. similarly to the chimeras made by irradiation. However. the number of donor cells present is much smaller in microchimeras than in macrochimeras made by irradiation. and this likely affects the relative contribution of various mechanisms to the tolerant phenotype. For example. it is unlikely that only a few donor DC that make their way to the recipient thymus would be able to completely delete donor reactive T cells (Plate 20.3). but there may be enough to activate autoregulatory circuits. In the meanwhile. other studies confirmed that passenger leukocytes persisted in experimental animals and in humans. but the authors did not necessarily agree with our interpretation [92.93, 194-201] .
I nitially this discovery did not fit easily into the current understanding of donor DC in transplantation immunobiology. It was not immediately clear how the most potentially potent allogeneic simulator could survive long term in a recipient who no longer required immunosuppression. This was especially true for DC in the periphery, even though freshly isolated DC from non lymphoid tissues are relatively inefficient antigenpresenting cells. It was clear, however. that long-term persistence of donor DC in the allograft was associated with freedom from chronic rejection [120] and, therefore, they might mediate tolerogenic reactions. In addition. trafficking of donor hematopoietic stem and progenitor cells from the allograft to the recipient bone marrow and thymus was not widely appreciated. However. analogies were drawn between this situation and that of mixed allogeneic chimeras achieved with irradiation. In the periphery. only a few studies had suggested that DC might mediate tolerogenic reactions [202, 203] . More recently. however. there is an increasing awareness that DC can and do mediate eventual 'nonresponsiveness' [ 21. 204-207] . How this is achieved is covered in greater detail in Chapter 26. In the non transplantation setting, there is now convincing evidence that DC can mediate both stimulatory and tolerogenic immune reactions. The context of presentation is certainly of great importance in determining which pathway is chosen. This is also true for transplantation. Without transient immunosuppression. mature DC invariably precipitate rejection that causes graft failure. With immunosuppression. acute rejection is avoided and the persistence of donor DC is associated with allograft protection from CR [120] . These probably arise from engrafted stem cells and/or other precursors. Emerging details about the mechanism(s) in stimulatory and tolerogenic reactions invol\ed are cmered in Chapter 26. What. then. has been learned ahout the immune system. MHC antigens and the role of DC in the experimcnt of transplantation'! First. it is dear that an immune system has 'Iocal" properties. which greatly complicate the ability to take an organ from one person and implant it into another one. We have also learned that MHC antigens and DC both play important roles in defining these local properties. and successful long-term freedom from rejection prohahly requires transfer of the donor immune system. DC appear to exert this etlcct via their ability to stimulate immune reactions that either prevent or 1~lcilitate assimilation of the donor immune system and its accompanying organ into the recipient. which in turn depends on their phenotype and maturational stage. Thus. in a generic sense. at least part of the 'Ioca r properties of the immune system are self-defined by DC. and the other immune cells with which they interact. both in the thymus and in the periphery. However. this occurs in the context of the environment and is dependent on. but not strictly limited hy. the recipient MHC genes,antigens. Consequently. it appears that the local properties of the immune system and MHC antigens were not designed for the purpose of preventing allogeneic transplantation but to enable species adaptability [20X-210] . The key to understanding. and thus controlling. the immune system for the purpose of transplantation will come from a knowledge of its local and nonlocal properties so that the latter can be exploited which highlights tissue macrophages. Note the presence of the donor dendritic-shaped cell in the recipient thymus (arrow and inset). The 'shrunken' medulla in this recipient can be attributed to the transient 2-week course of FK506, which is known to cause damage to the thymic medulla [214] . It may also create a milieu conducive to the recruitment of donor DC progenitors [3, 214) . (B) Donor DC can also be detected in the spleen. This is a section of recipient spleen, obtained 30 days after liver transplantation and double stained for donor MHC class II (red) and OX62, an integrin, known to be expressed by rat DC [213] . Note the presence of the yellow, doubly labeled donor DC. (C) Challenge donor heart allograft 100 days after transplantation in a recipient rendered tolerant to the donor by a previous liver allograft. This section is double stained for donor MHC class II (red) and OX62. Note the red, single positive MHC class W donor interstitial cell (large arrow) and yellow, double positive donor DC. Even though this recipient received no immunosuppression, donor DC persisted in the challenge allograft and it was resistant to chronic rejection (120).
